{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:00:42Z","timestamp":1790596842236,"version":"4.1.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T00:00:00Z","timestamp":1382054400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0077169","type":"journal-article","created":{"date-parts":[[2013,10,18]],"date-time":"2013-10-18T17:07:01Z","timestamp":1382116021000},"page":"e77169","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":154,"title":["Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Zhi-Kang","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suo-Di","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,10,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkr442","article-title":"Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis","volume":"67","author":"MA Cataldo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/491708","article-title":"Vancomycin: a 50-year reassessment","volume":"42 Suppl 1","author":"RC Moellering Jr","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42 Suppl 1","author":"DP Levine","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42 Suppl 1","author":"MJ Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","article-title":"Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity","volume":"23","author":"W Darko","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/clinids\/18.4.533","article-title":"Serum vancomycin concentrations: Reappraisal of their clinical value","volume":"18","author":"TG Cantu","year":"1994","journal-title":"Clin Infect Dis"},{"key":"ref7","first-page":"110","article-title":"Vancomycin: Is it necessary the therapeutic drug monitoring?","volume":"16","author":"GN Karachalios","year":"1998","journal-title":"Epitheorese Klinikes Farmakologias kai Farmakokinetikes"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/106002809402801212","article-title":"Vancomycin serum concentration monitoring: a continued debate","volume":"28","author":"RD Pryka","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/clinids\/18.4.544","article-title":"Monitoring serum vancomycin levels: climbing the mountain because it is there?","volume":"18","author":"RC Moellering Jr","year":"1994","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"M Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"ref11","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","author":"K Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"BP Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"TP Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"G Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"LK Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref16","first-page":"250","article-title":"Focused Conference Group: P13 - Maximising benefits and minimizing harms from drugs vancomycin dosing and monitoring in children: Compliance with guidelines in a belgian teaching hospital","volume":"107","author":"P De Cock","year":"2010","journal-title":"Basic Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijantimicag.2011.08.017","article-title":"Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study","volume":"39","author":"J Li","year":"2012","journal-title":"Int J Antimicrob Ag"},{"key":"ref18","first-page":"91","article-title":"Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function","volume":"48","author":"GT Khotaei","year":"2010","journal-title":"Acta Medica Iranica"},{"key":"ref19","first-page":"1625","article-title":"[Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children]","volume":"15","author":"P Mariani-Kurkdjian","year":"2008","journal-title":"Arch Pediatr"},{"key":"ref20","first-page":"410","article-title":"[Monitoring vancomycin in an intensive care unit: A retrospective survey on 66 patients]","volume":"41","author":"D Commandeur","year":"2011","journal-title":"Med Mal Infect"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2223\/JPED.617","article-title":"Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections","volume":"72","author":"AGAC Reis","year":"1996","journal-title":"Jornal de Pediatria"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00044011-200019030-00006","article-title":"Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function - Multiple daily doses may be preferable","volume":"19","author":"F Pea","year":"2000","journal-title":"Clin Drug Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00007691-199706000-00004","article-title":"Special considerations for monitoring vancomycin concentrations in pediatric patients","volume":"19","author":"MV Miles","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.medmal.2011.09.014","article-title":"Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia","volume":"41","author":"C Hochart","year":"2011","journal-title":"Med Mal Infect"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1413-8670(10)70041-6","article-title":"Vancomycin: the need to suit serum concentrations in hemodialysis patients","volume":"14","author":"LL Marengo","year":"2010","journal-title":"Braz J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1345\/aph.1P588","article-title":"Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients","volume":"45","author":"LS Eiland","year":"2011","journal-title":"Ann Pharmacother"},{"key":"ref27","unstructured":"Wells GS, Shea B, O'Connell D, Peterson J, Welch V, et al<\/etal>. (2005) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm<\/ext-link> (20 Apirl 2013, data last accessed)."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"CB Begg","year":"1994","journal-title":"Biometrics"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1177\/106002809402801201","article-title":"Impact of vancomycin therapeutic drug monitoring on patient care","volume":"28","author":"TE Welty","year":"1994","journal-title":"Ann Pharmacother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0009-9236(96)90060-0","article-title":"Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies","volume":"60","author":"MD Fernandez de Gatta","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1248\/bpb.26.876","article-title":"Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin","volume":"26","author":"T Iwamoto","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"ref33","first-page":"220","article-title":"Evaluation of the usefulness of vancomycin dosage design based on pharmacokinetics\/pharmacodynamics theory","volume":"55","author":"S Sato","year":"2007","journal-title":"Jpn J Chemother"},{"key":"ref34","first-page":"233","article-title":"Efficacy and safety for vancomycin in uncomplicated catheter-related bloodstream infection by coagulase negative Staphylococcus","volume":"58","author":"T Mochizuki","year":"2010","journal-title":"Jpn J Chemother"},{"key":"ref35","first-page":"295","article-title":"Clinical application of drug monitoring of vancomycin","volume":"11","author":"YZ Huang","year":"2011","journal-title":"Chin J Infec Chemother"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1378\/chest.130.4.947","article-title":"Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices","volume":"130","author":"MN Jeffres","year":"2006","journal-title":"Chest"},{"key":"ref37","first-page":"329","article-title":"Necessarity of therapeutic drug monitoring of vancomycin in clinical use: a systematicreview","volume":"25","author":"C Zhang","year":"2009","journal-title":"Chin J Clin Pharmacol"},{"key":"ref38","first-page":"195","article-title":"Population pharmacokinetics of vancomycin in hospitalized adult patients at a Malaysian tertiary care hospital","volume":"44","author":"C Long","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"ref39","first-page":"196","article-title":"Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis","volume":"63","author":"LM van de Vijsel","year":"2010","journal-title":"Can J Hosp Pharm"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5414\/CPP46140","article-title":"Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock","volume":"46","author":"M Vazquez","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref41","first-page":"232","article-title":"Elimination of vancomycin by continuous arteriovenous hemofiltration","volume":"9","author":"AH Lau","year":"1988","journal-title":"Child Nephrol Urol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jac\/45.3.329","article-title":"High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures","volume":"45","author":"F Pea","year":"2000","journal-title":"J Antimicrob Chemoth"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/1078155209355847","article-title":"Pharmacokinetics of vancomycin in adult cancer patients","volume":"16","author":"H Al-Kofide","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5414\/CP201456","article-title":"Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital","volume":"49","author":"EF Badran","year":"2011","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5414\/CNP72286","article-title":"Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing","volume":"72","author":"L Golestaneh","year":"2009","journal-title":"Clin Nephrol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.burns.2009.08.010","article-title":"Vancomycin pharmacokinetics in patients with severe burn injuries","volume":"36","author":"M Dolton","year":"2010","journal-title":"Burns"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0077169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:14:33Z","timestamp":1540005273000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0077169"}},"subtitle":[],"editor":[{"given":"Alfonso","family":"Carvajal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,10,18]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,10,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0077169","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,18]]}}}